《特发性膜性肾病与成人肾病综合征的免疫抑制治疗》内容预览

Background
Idiopathic membranous nephropathy (IMN) is the most common form of nephrotic syndrome in adults. The disease shows a benign or indolent course in the majority of patients, with a rate of spontaneous complete or partial remission of nephrotic syndrome as high as 30% or more. Despite this, 30-40% of patients progress toward end-stage renal failure (ESRF) within 5-15 years.
Objectives
To assess the benefits and harms of immunosuppressive treatment for IMN in adults. 、
Search strategy
We searched the Cochrane Renal Group Specialised Register (December 2003), The Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2003), MEDLINE, Pre-MEDLINE (1966 - December 2003), EMBASE (1980 - December 2003), reference lists of nephrology textbooks, review articles, prospective trial registers, relevant trials, abstracts from nephrology scientific meetings and the Internet without language restriction. We contacted principal investigators of controlled studies.
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs comparing any immunosuppressive interventions for the treatment of IMN in adults.
Data collection and analysis
Two reviewers independently assessed and extracted information. Information was collected on method, participants, interventions and outcomes (death, ESRF, proteinuria, serum creatinine, GRF, remission, adverse events).

《特发性膜性肾病与成人肾病综合征的免疫抑制治疗》完整版下载地址：
http://ziyuan.iiyi.com/source/down/2310114.html